RGUP20037, Zhang, NRG-GU008, Prostate Cancer, Abiraterone Acetate,Apalutamide, Prednisone
Research Question:
How well does adding apalutamide, abiraterone acetate, and prednisone to the usual
hormone therapy and radiation therapy work compared to the usual hormone therapy and
radiation therapy in treating patients with node-positive prostate cancer after surgery?
Basic Study Information
Purpose:
This phase III trial studies how well adding apalutamide, abiraterone acetate, and
prednisone to the usual hormone therapy and radiation therapy works compared to the
usual hormone therapy and radiation therapy in treating patients with node-positive
prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor
cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of
prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth
of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks
some of the enzymes needed for androgen production and may cause the death of prostate
cancer cells that need androgens to grow. Prednisone may help abiraterone acetate
work better by making tumor cells more sensitive to the drug. Adding apalutamide and
abiraterone acetate with prednisone to the usual usual hormone therapy and radiation
therapy after surgery may stabilize prostate cancer and prevent it from spreading
or extend time without disease spreading compared to the usual approach.
Location: University of Rochester Medical Center
Study Reference #: RGUP20037
Lead Researcher (Principal Investigator)
Lead Researcher:
Hong Zhang
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search